Success Metrics

Clinical Success Rate

100.0%

Based on 2 completed trials

Completion Rate

100%(2/2)

Active Trials

1(13%)

Results Posted

50%(1 trials)

Phase Distribution

Ph not_applicable

13%

Ph phase_2

50%

Ph phase_3

38%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution8 total trials

Phase 2Efficacy & side effects

4(50.0%)

Phase 3Large-scale testing

3(37.5%)

N/ANon-phased studies

1(12.5%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

66.7%

2 of 3 finished

Non-Completion Rate

33.3%

1 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(5)

Completed(2)

Terminated(1)

Detailed Status

Not yet recruiting3

Completed2

Withdrawn1

Enrolling by invitation1

Recruiting1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

100.0%

Most Advanced

Phase 3

Trials by Phase

Phase 24 (50.0%)

Phase 33 (37.5%)

N/A1 (12.5%)

Trials by Status

withdrawn113%

enrolling_by_invitation113%

not_yet_recruiting338%

completed225%

recruiting113%

Recent Activity

1 active trials

Showing 5 of 8

enrolling_by_invitationphase_2

Clinical Trials (8)

Showing 8 of 8 trials

NCT06790095Phase 2

TRACK-TBI Precision Medicine Part 3 - Option II

Enrolling By Invitation

NCT07653581Phase 3

rhTPO + CsA vs CsA in the Treatment of LR-MDS With Thrombocytopenia

Not Yet Recruiting

NCT07523009Phase 2

CsA+EPAG/HPAG+Romiplostim N01 in the Treatment of Newly-diagnosed SAA/TD-NSAA

Withdrawn

NCT07558434Phase 2

CsA+EPAG/HPAG+Romiplostim N01 in Newly-diagnosed SAA/TD-NSAA

Not Yet Recruiting

NCT07548671Phase 3

Enarodustat + CsA vs CsA in Newly Diagnosed TD-NSAA

Not Yet Recruiting

NCT05936086Not Applicable

A Randomized Controlled Study of High-dose Cyclophosphamide Induction Therapy in Adult Patients With HLH

Recruiting

NCT00256750Phase 3

Belatacept Evaluation of Nephroprotection and Efficacy as First-line Immunosuppression (BENEFIT)

Completed

NCT00948727Phase 2

Cyclosporine Dose Adjustment According to Calcineurin Activity After Allogeneic Hematopoietic Stem-cell Transplantation

Completed

All 8 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 8